← Back to Search

129Xe MRI for Lung Disease

Phase 2

Recruiting

Led By Joseph Mammarappallil, MD

Research Sponsored by Bastiaan Driehuys

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 3-6 months post-treatment

Awards & highlights

Study Summary

This trial aims to study how 3 biomarkers change when people respond to treatments. It's funded by the US National Institutes of Health.

Who is the study for?

This trial is for adults over 18 with interstitial lung disease, thromboembolic pulmonary hypertension, or who are healthy volunteers. Participants must be able to give consent and follow the study plan. Smokers or those with recent respiratory illness, certain heart conditions, low oxygen levels, MRI contraindications, inability to hold breath for 10 seconds, pregnancy or lactation are excluded.Check my eligibility

What is being tested?

The study tests how three biomarkers from a special type of MRI using hyperpolarized Xenon gas (129Xe) change in response to interventions like oxygen administration. It aims to improve understanding of various lung diseases and their treatment.See study design

What are the potential side effects?

While not explicitly listed in the provided information, potential side effects may include discomfort from wearing the MRI vest coil and holding one's breath during imaging. Oxygen administration can sometimes cause dryness of nasal passages or mild headache.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 3-6 months post-treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 3-6 months post-treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3-6 months post-treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in RBC (red blood cell) Chemical Shift After Oxygen Administration

Change in RBC Oscillation Amplitude Post Therapy

Change in RBC to Membrane Ratio Pre and Post Transfusion or Apheresis

Trial Design

3Treatment groups

Active Control

Group I: Transfusion and Phlebotomy PatientsActive Control1 Intervention

Individuals receiving treatment for their blood hemoglobin levels or are a healthy volunteer who is planning to donate blood.

Group II: Oxygen Administration PatientsActive Control2 Interventions

Individuals diagnosed with a chronic blood clot in their lungs and are planning on having surgery to remove it (CTEPH), or have an interstitial lung disease (ILD), or have dyspnea, or are a healthy volunteer.

Group III: Acute or Chronic Pulmonary Embolism PatientsActive Control1 Intervention

Individuals recently diagnosed with a blood clot in their lungs.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Institutes of Health (NIH)NIH

2,701 Previous Clinical Trials

7,506,725 Total Patients Enrolled

4 Trials studying Anemia

577 Patients Enrolled for Anemia

Bastiaan DriehuysLead Sponsor

14 Previous Clinical Trials

956 Total Patients Enrolled

Joseph Mammarappallil, MDPrincipal InvestigatorDuke University

1 Previous Clinical Trials

147 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are any additional participants being sought for this experiment?

"This clinical trial, which initially began enrolling patients on September 25th 2023 is no longer seeking participants. Nevertheless, there are still 762 other trials currently recruiting at this time according to the information hosted online."

Answered by AI

What measures have been taken to ensure the safety of those undergoing Transfusion and Phlebotomy treatments?

"Our efficacy assessment at Power placed Transfusion and Phlebotomy Patients on a scale of 1 to 3, with the latter indicating that there is evidence for safety but not yet any data demonstrating its effectiveness as this is currently only in Phase 2."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

129Xe MRI Cardiopulmonary

Bastiaan Driehuys 2024. "129Xe MRI Cardiopulmonary". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06038630.

All > Pulmonary Embolism > Pulmonary Hypertension